Investigating of the Effect of Ginger Supplementation in Patients with Parkinson’s Disease

INTERVENTION: Intervention 1: Intervention group: Participants in the intervention group will receive two 500 milligram tablets containing standardized ginger powder daily for twelve weeks. Each tablet contains 500 milligrams of standardized ginger powder, equivalent to 25 milligrams of active gingerol. The tablets should be consumed with one of the main meals, either lunch or dinner. The ginger tablets are manufactured by Dineh Iran Industrial Comple Xand have been matched in size, shape, color, and smell with the placebo tablets. Intervention 2: Control group: Participants in the control group will receive two 500 milligram tablets containing corn flour as a placebo daily for twelve weeks. The placebo tablets have been matched in size, shape, color, and smell with the ginger tablets to ensure that participants and researchers remain blinded to group allocation. CONDITION: Parkinson’s disease. ; Parkinson's disease PRIMARY OUTCOME: Change in Parkinson’s disease severity based on the total score of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale. Timepoint: Assessment of Parkinson’s disease severity at baseline before the start of the intervention and at the end of week twelve after completion of the intervention. Method of measurement: Movement Disorder Society Unified Parkinson’s Disease Rating Scale. SECONDARY OUTCOME: Change in quality of life in patients with Parkinson’s disease. Timepoint: Assessment of quality of life in patients with Parkinson’s disease at baseline before the start of the intervention and at the end of week twelve of the intervention. Method of measurement: Parkinson’s disease quality of life questionnaire. Change in serum level of Glutathione peroxidase. Timepoint: Measurement of serum Glutathione peroxidase at baseline before the start of the intervention and at the end of week twelve of the intervention. Method of measurement: Measurement of serum Glutathione peroxidase using standard biochemical methods. Change in serum level of Superoxide dismutase. Timepoint: Measurement of serum Superoxide dismutase at baseline before the start of the intervention and at the end of week twelve of the intervention. Method of measurement: Measurement of serum Superoxide dismutase using standard biochemical methods. Change in serum total antioxidant capacity. Timepoint: Measurement of serum total antioxidant capacity at baseline before the start of the intervention and at the end of week twelve of the intervention. Method of measurement: Measurement of serum total antioxidant capacity using standard biochemical methods. Change in serum total oxidant status. Timepoint: Measurement of serum total oxidant status at baseline before the start of the intervention and at the end of week twelve of the intervention. Method of measurement: Measurement of serum total oxidant status using standard biochemical methods. INCLUSION CRITERIA: Age between 50 and 80 years Body Mass Inde X(BMI) greater than 18.5 Patients willing to participate in the study and able to provide written informed consent Diagnosis of Parkinson’s disease confirmed by a neurologist based on established diagnostic criteria Stable medication regimen for at least one month prior to the beginning of the study